skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Impact of telmisartan in modifying vascular risk

Review

(2458) Views  (810) Full article downloads

Authors: Jean-Philippe Baguet, Olivier Ormezzano, Gilles Barone-Rochette

Published Date June 2010 Volume 2010:3 Pages 81 - 89
DOI: http://dx.doi.org/10.2147/IBPC.S6707

Jean-Philippe Baguet, Olivier Ormezzano, Gilles Barone-Rochette

Clinique de Cardiologie, Centre Hospitalier Universitaire de Grenoble, Grenoble, France

Abstract: Telmisartan, a selective angiotensin II type 1 receptor blocker (ARB), has been investigated in many trials, in particular, in order to assess its antihypertensive effect in various situations and its ability to protect organs susceptible to hypertension. In addition to its antihypertensive properties, it has positive metabolic and vascular effects (partly because of its sustained action). Several large-scale trials have focused on the effect of telmisartan on cardiovascular morbidity and mortality, including comparisons of that with an angiotens-inconverting enzyme inhibitor in subjects at high vascular risk. Telmisartan was used in the largest ARB research programme (the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial [ONTARGET] and Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease [TRANSCEND] trial).

Keywords: angiotensin II receptor blocker cardiovascular risk, hypertension, blood pressure, renin–angiotensin–aldosterone system






 

Other articles by Professor Jean-Philippe Baguet



Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination
Critical appraisal and pooled analysis of telmisartan alone or in combination with hydrochlorothiazide for achieving blood pressure goals
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
Clinical utility of fixed-combination telmisartan–amlodipine in the treatment of hypertension
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Telmisartan and cardioprotection
Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University